These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

74 related items for PubMed ID: 1687721

  • 21. Strain differences in change in airway responsiveness after repeated antigenic challenge in three strains of rats.
    Chiba Y, Misawa M.
    Gen Pharmacol; 1993 Sep; 24(5):1265-72. PubMed ID: 8270186
    [Abstract] [Full Text] [Related]

  • 22. Effect of an orally active Th1/Th2 balance modulator, M50367, on IgE production, eosinophilia, and airway hyperresponsiveness in mice.
    Kato Y, Manabe T, Tanaka Y, Mochizuki H.
    J Immunol; 1999 Jun 15; 162(12):7470-9. PubMed ID: 10358202
    [Abstract] [Full Text] [Related]

  • 23. Optimisation of the sensitisation conditions for an ovalbumin challenge model of asthma.
    Smith N, Broadley KJ.
    Int Immunopharmacol; 2007 Feb 15; 7(2):183-90. PubMed ID: 17178385
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effect of TYB-2285 on antigen-induced airway responses in sheep.
    Abraham WM, Ahmed A, Cortes A, Sielczak M, Wantanabe A.
    Pulm Pharmacol; 1996 Feb 15; 9(1):49-58. PubMed ID: 8843510
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Inhalation of the Rho-kinase inhibitor Y-27632 reverses allergen-induced airway hyperresponsiveness after the early and late asthmatic reaction.
    Schaafsma D, Bos IS, Zuidhof AB, Zaagsma J, Meurs H.
    Respir Res; 2006 Sep 26; 7(1):121. PubMed ID: 17002806
    [Abstract] [Full Text] [Related]

  • 31. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS.
    Acta Ophthalmol; 2009 Aug 26; 87(5):549-54. PubMed ID: 18631332
    [Abstract] [Full Text] [Related]

  • 32. Pharmacodynamics of the new H1-antagonist 3-amino-9,13b-dihydro-1H-dibenz[c,f]imidazo[1,5-a]azepine hydrochloride in volunteers.
    Adamus WS, Oldigs-Kerber J, Lohmann H.
    Arzneimittelforschung; 1987 May 26; 37(5):569-72. PubMed ID: 2887173
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Ocular comfort and drying effects of three topical antihistamine/mast cell stabilizers in adults with allergic conjunctivitis: a randomized, double-masked crossover study.
    Torkildsen GL, Ousler GW, Gomes P.
    Clin Ther; 2008 Jul 26; 30(7):1264-71. PubMed ID: 18691985
    [Abstract] [Full Text] [Related]

  • 37. Inhibitory effect of epinastine on superoxide generation by rat neutrophils.
    Fukuishi N, Kan T, Hirose K, Akagi R, Akagi M.
    Jpn J Pharmacol; 1995 Aug 26; 68(4):449-52. PubMed ID: 8531420
    [Abstract] [Full Text] [Related]

  • 38. Pharmacological studies on the novel antiallergic drug HQL-79: I. Antiallergic and antiasthmatic effects in various experimental models.
    Matsushita N, Hizue M, Aritake K, Hayashi K, Takada A, Mitsui K, Hayashi M, Hirotsu I, Kimura Y, Tani T, Nakajima H.
    Jpn J Pharmacol; 1998 Sep 26; 78(1):1-10. PubMed ID: 9804056
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.